36 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Araxes Pharma LLC portfolio ends in Mar 2034, and more of its terms end in 2034 (13) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2034
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2034 · High confidence
Also notable
Ends Oct 2034 · High confidence
Also notable
Ends May 2038 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends Oct 2034 · High confidence
Also notable
Ends Nov 2036 · High confidence
Also notable
Ends Apr 2036 · High confidence
Covalent Inhibitors of Kras G12C
US 9,227,978
Cited by 152 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Substituted Quinazolines as Inhibitors of Kras G12C
US 9,840,516
The most cited patent in this portfolio, cited by 180 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2034.
Covalent Inhibitors of Kras
US 10,745,385
Cited by 51 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
1-(3-(6-(3-Hydroxynaphthalen-1-YL)BENZOFURAN-2-YL)AZETIDIN-1 YL)PROP-2-EN-1-ONE Derivatives and Similar Compounds as Kras G12C Modulators for Treating Cancer
US 11,279,689
Cited by 38 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Fused Bicyclic Benzoheteroaromatic Compounds and Methods of Use Thereof
US 11,274,093
Cited by 30 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Substituted Quinazoline Compounds and Methods of Use Thereof
US 10,144,724
Cited by 38 later US patents, top 10% of utility patents granted in 2018 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof
US 10,414,757
Cited by 31 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2036.
Substituted Quinazoline Compounds and Methods of Use Thereof
US 10,246,424
Cited by 28 later US patents, top 10% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Substituted Quinazoline Compounds and Methods of Use Thereof (US 10,351,550) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 2 fees due Feb 6 to 13, 2027 · next Feb 6
- 1 fee due Mar 17, 2027The maintenance fee for 2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof (US 10,414,757) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Fused-Tricyclic Inhibitors of Kras and Methods of Use Thereof (US 10,428,064) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 2 fees due Jul 5 to 23, 2027 · next Jul 5
- 2 fees due Nov 12, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,227,978 | Covalent Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 9,926,267 | Covalent Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 10,273,207 | Covalent Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 10,882,847 | Inhibitors of Kras G12C Mutant Proteins In force · High confidence | In force | High confidence | |
| US RE50,527 | Covalent Inhibitors of Kras G12C In force · Low confidence | In force | Low confidence | |
| US 9,840,516 | Substituted Quinazolines as Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 10,111,874 | Combination Therapies for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,144,724 | Substituted Quinazoline Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,351,550 | Substituted Quinazoline Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,370,386 | Substituted Quinolines as Inhibitors of Kras G12C In force · High confidence | In force | High confidence |
Also on record, not counted in the 36: 10 patents ended · 4 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.